Dose and frequency of interferon treatment matter: INCOMlN and OPTIMS

Journal of Neurology, Supplement

Volumn 250, Issue 4, 2003, Pages 9-14

  Durelli, Luca ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Clinical trial; Interferon beta 1a; Interferon beta 1b; Multiple sclerosis; Relapse; Relapsing remitting

Indexed keywords

BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; IBUPROFEN; INTERFERON BETA SERINE; INTERLEUKIN 10; NEOPTERIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; GENE EXPRESSION; HEADACHE; HUMAN; INJECTION; INJECTION PAIN; INJECTION SITE; INTRACELLULAR SPACE; LOW DRUG DOSE; MEDICAL ETHICS; MOLECULE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REGULATORY MECHANISM; RELAPSE; REMISSION; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; TREATMENT OUTCOME;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 0347593917     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59: 1507-1517
2. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Independent Comparison of Interferon (INCOMIN) Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
3. Durelli L, Verdun E, Clerico M, Versino E (2002) Immunomodulatory agents in multiple sclerosis: clinical trials and therapy. In: Gilman S (ed) MedLink Neurology. MedLink Corporation. Available at www.medlink.com, San Diego
4. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
5. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
6. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
7. Jacobs L, Cookfair DL, Rudick RA and The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
8. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC et al.(1993) Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340
9. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
10. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
11. PRISMS (Prevention of Relapses and Disability by Interferon beta-1 a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504
12. Rice GP, Ebers GC, Lublin FD, Knobler RL (1999) Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 52:1893-1895
13. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J (1999) Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141
14. The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53:679-686
15. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627
16. Williams GJ, Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res 18:967-975
17. Witt PL, Storer BE, Bryan GT, Brown RR, Flashner M, Larocca AT, Colby CB, Borden EC (1993) Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother 13:191-200
18. Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L (in press) High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be chronically maintained even in patients with a good treatment response. J Neurol Sci